Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma progression

Wang, Mao‐Ze; Niu, Jie; Ma, Hui-Jian; Dad, Haseeb Anwar; Shao, Hu; Yuan, Tiejun; Peng, Li‐Hua

doi:10.1016/j.jconrel.2020.03.023

Cited by 66 publications

(33 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that resistance of tumor cells against TRAIL is partly due to the overexpressions of apoptosis inhibitory molecules, cellular Fas-associated death domain protein–like IL-1β–converting enzyme-inhibitory protein (c-FLIP) and inhibitor of apoptosis proteins (IAPs) (i.e., survivin) ( 20 ), as well as the lack of expressions of caspases 3 and 8 ( 21 ). To verify whether NIR irritation can switch TRAIL-resistant melanoma cells into a sensitive state, we examined c-FLIP and IAP levels in cells with different treatments.…”

Section: Resultsmentioning

confidence: 99%

Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL–programmed therapy against melanoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Melanoma is an aggressive cancer with rapid progression, relapse, and metastasis. Systemic therapies for melanoma exhibit limited anticancer potential and high toxicity. Here, we developed the outer membrane vesicles derived from transgenic Escherichia coli, modified with αvβ3 integrin peptide targeting ligand and indocyanine green (named as I-P-OMVs), to induce the transdermal photo-TRAIL-programmed treatment in skin melanoma.-OMVs, which are outer membrane vesicles derived from transgenic Escherichia coli, modified with αvβ3 integrin targeting ligand and indocyanine green (named as I-P-OMVs), to induce the transdermal photo-TRAIL–programmed treatment in skin melanoma. I-P-OMVs exhibited excellent stratum corneum penetration and specificity to melanoma. Upon near-infrared irritation, I-P-OMVs not only induced photothermal-photodynamic responses against primary melanoma spheroids but also activated TRAIL-induced apoptosis in disseminated tumor cells, resulting in a complete eradication of melanoma. I-P-OMVs are the first nanoplatforms to induce transdermal photo-TRAIL–programmed therapy in melanoma with enhanced antitumor performance and high safety, having great potential in cancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL–programmed therapy against melanoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Transdermal siRNA delivery by pH-responsive micelles has been successfully achieved for melanoma therapy [289]. This study provides the design of pH-switchable cationic micelles as transdermal gene delivery nanoplatform with targeting effects and pH-triggered release.…”

Section: Ph-responsive Carriers/polymersmentioning

confidence: 99%

Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting

Rahim

Jan

Khan

et al. 2021

Cancers

113

View full text Add to dashboard Cite

The tumor-specific targeting of chemotherapeutic agents for specific necrosis of cancer cells without affecting the normal cells poses a great challenge for researchers and scientists. Though extensive research has been carried out to investigate chemotherapy-based targeted drug delivery, the identification of the most promising strategy capable of bypassing non-specific cytotoxicity is still a major concern. Recent advancements in the arena of onco-targeted therapies have enabled safe and effective tumor-specific localization through stimuli-responsive drug delivery systems. Owing to their promising characteristic features, stimuli-responsive drug delivery platforms have revolutionized the chemotherapy-based treatments with added benefits of enhanced bioavailability and selective cytotoxicity of cancer cells compared to the conventional modalities. The insensitivity of stimuli-responsive drug delivery platforms when exposed to normal cells prevents the release of cytotoxic drugs into the normal cells and therefore alleviates the off-target events associated with chemotherapy. Contrastingly, they showed amplified sensitivity and triggered release of chemotherapeutic payload when internalized into the tumor microenvironment causing maximum cytotoxic responses and the induction of cancer cell necrosis. This review focuses on the physical stimuli-responsive drug delivery systems and chemical stimuli-responsive drug delivery systems for triggered cancer chemotherapy through active and/or passive targeting. Moreover, the review also provided a brief insight into the molecular dynamic simulations associated with stimuli-based tumor targeting.

show abstract

“…Overall, polymeric NPs are increasingly used for gene delivery to the skin. However, it should be noted that most of the studies are still in an early preclinical phase, which leaves the actual translational value ambiguous [ 48 , 50 , 51 ]. Although polymeric NPs do not have the natural infective ability of viruses, by leveraging our understanding of cell biology and bioengineering of synthetic biomaterials, the development of stable, multifunctional, and highly effective gene delivery systems has advanced [ 52 ].…”

Section: Delivery Of Gene Therapies To the Skinmentioning

confidence: 99%

Gene Delivery to the Skin – How Far Have We Come?

Ain

Campos

Huynh

et al. 2021

Trends in Biotechnology

View full text Add to dashboard Cite

Gene therapies are powerful tools to prevent, treat, and cure human diseases. The application of gene therapies for skin diseases received little attention so far, despite the easy accessibility of skin and the urgent medical need. A major obstacle is the unique barrier properties of human skin, which significantly limits the absorption of biomacromolecules, and thus hampers the efficient delivery of nucleic acid payloads. In this review, we discuss current approaches, successes, and failures of cutaneous gene therapy and provide guidance toward the development of next-generation concepts. We specifically allude to the delivery strategies as the major obstacle that prevents the full potential of gene therapies – not only for skin disorders but also for almost any other human disease.

show abstract

Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma progression

Cited by 66 publications

References 60 publications

Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL–programmed therapy against melanoma

Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL–programmed therapy against melanoma

Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting

Gene Delivery to the Skin – How Far Have We Come?

Contact Info

Product

Resources

About